简介：AIM:Totestthehypothesisthatamblyopicneuroretinamayhaveanalteredthicknesswhencomparedtothenormal.·METHODS:Twenty-fiveamblyopic,youngpatientsbetweentheagesof7and11yearsoldwerestudied.Theinterestedneuroretinaareasaredefinedinto10sub-regionsaccordingtosuperior-inferior,nasal-temoral,andperi-paraaxis,whichcrossthefovelastructure.Thethicknessesoften,definedmacularregionswereseparatelymeasuredbyopticalcoherencetomography(OCT)andanalyzedbyt-test.·RESULTS:Theaveragethicknessofneuroretinaintheexactfoveolaoftheamblyopiceyesislargerthanthatofnormaleyes(P<0.05),buttheothernineregionshavenosignificantdifference.Interestingly,inboththenormalandamblyopiceyes,thetemporalarealooksthinnerthanotherquadrants(P<0.05).·CONCLUSION:Thicknessalterationmaybeassociatedwithamblyopicdisordersinyoungpatients.Studyingalargervolumeofsubjectsofsimilarageisrequiredtoconfirmthisobservation.

简介：AIM:Tocomparetheregularityandaccuracyoflaserinsitukeratomileusis(LASIK)flapscreatedbytheZiemerFEMTOLDV'Classic'(Ziemer'Classic')andZiemerFEMTOLDVCrystalLinefemtosecondlaser(ZiemerCrystalLine).METHODS:Fourier-domainopticalcoherencetomography(RTVueOCT)wasusedtomeasurethemorphologyof200LASIKflapsof100consecutivepatientscreatedwiththeZiemerClassic(100flaps)ortheZiemerCrystalLine(100flaps)atoneweekpostoperatively.Flapthicknesswasevaluatedat36specifiedmeasurementpointsoneachflap.Forallprocedureswithbothlasers,thenominalflapthicknesswas110μm.RESULTS:ThemeanflapthicknessoftheZiemerCrystalLinegroup(102.49±2.68μm)wasthinnerthanthatoftheZiemerClassicgroup(107.65±5.09μm)(P<0.01).Averagethicknessofallflapswasuniformwithin4μmatallmeasurementpoints.TheflapsintheZiemerCrystalLinegroupweremoreregularthanthoseintheZiemerClassicgroupwhenmeasuredfromthecentertotheperiphery.Themaximumdeviationfromthenominal110μmof36measurementswas8μmintheZiemerClassicgroup,whileintheZiemerCrystalLinegroupitwas9μm.Withinthe3600measurementsonthe100eyes,differencesgreaterthan20μmwereobserved0.14%intheZiemerClassicgroup,and0.04%intheZiemerCrystalLinegroup.CONCLUSION:TheflapscreatedwiththeZiemerFEMTOLDVCrystalLinefemtosecondlaseraremoreuniformandthinnerthanthosecreatedbytheZiemerFEMTOLDVClassicfemtosecondlaser.

简介：AIM:Toassesstheeffectofmyopiaonthethicknessofretinalnervefiberlayer(RNFL)measuredby3Dopticalcoherencetomography(3D-OCT)inagroupofnonglaucomatousChinesesubjects.METHODS:Twohundredandfifty-eighteyesof258healthyChinesemyopicindividualswererecruitedandfourgroupswereclassifiedaccordingtotheirsphericalequivalent(SE):lowmyopia(n=42,-0.50

简介：AIM:Tofindouttheoutcomeoflaserphotocoagulationinclinicallysignificantmacularedema(CSME)byopticalcoherencetomography(OCT).·METHODS:Itwasaprospective,non-controlled,caseseriesstudyenrolling81eyesof64patientswithCSMEbetweenAugust2008andJanuary2010.AllpatientsreceivedmodifiedgridphotocoagulationwithfrequencydoubledNd:YAGlaser.Eachpatientwasevaluatedintermsofbest-correctedvisualacuity(BCVA)andregressionorprogressionofmaculopathyafterlasertherapyat1,3and6months.Spearman’scorrelationtestwasusedtoshowthecorrelationbetweenBCVAandtotalmacularvolume(TMV).Analysisofvariance(ANOVA)wasusedtocompareamonggroupsandindependentt-testwasusedtocompareineachgroup.·RESULTS:ThereishighcorrelationbetweenBCVAandTMV(P≤0.001).BCVAimprovedin50.6%,remainedstaticin39.5%anddeterioratedin9.9%patientsafter6monthoftreatment.TheBaselineTMV(meanandSD)were9.26±1.83,10.4±2.38,11.5±3.05,8.89±0.75and9.47±1.98mm3fordifferentOCTpatterns,ST(spongelikethickening),CMO(cystoidmacularedema),SFD(subfovealdetachment),VMIA(Vitreomacularinterfaceabnormality)andaverageTMVrespectively(P=0.04).After6monthsoflasertreatment,themeanTMVdecreasedfrom9.47±1.98mm3to8.77±1.31mm3(P=0.01).InSTtherewassignificantdecreaseinTMV,P=0.01,Furtherwithinthesegroupsat6months,theyweresignificantlydifferent,P=0.01.·CONCLUSION:OCTshowedthedifferentmorphologicalvariantofCSMEwhiletheresponseoftreatmentisdifferent.TMVdecreasedthemostandhenceshowedtheimprovementinvisionafter6monthsoflasertreatment.IntheeraofAntivascularendothelialgrowthfactors(VEGFs),efficacyoflaserseemstobeinshadowbutitisstillfirstlineoftreatmentindevelopingnationlikeNepalwhereantiVEGFsmaynotbeeasilyavailableandaffordable.